Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project

SZ. Usmani, A. Hoering, M. Cavo, JS. Miguel, H. Goldschimdt, R. Hajek, I. Turesson, JJ. Lahuerta, M. Attal, B. Barlogie, JH. Lee, S. Kumar, S. Lenhoff, G. Morgan, SV. Rajkumar, BGM. Durie, P. Moreau,

. 2018 ; 8 (12) : 123. [pub] 20181123

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19028045

Grant support
P50 CA186781 NCI NIH HHS - United States
U10 CA180819 NCI NIH HHS - United States
U10 CA180888 NCI NIH HHS - United States

PURPOSE: multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-term remissions and survival. The present study examines the clinical features of long-term survival as it correlates to depth of disease response. PATIENTS & METHODS: this was a multi-institutional, international, retrospective analysis of high-dose melphalan-autologous stem cell transplant (HDM-ASCT) eligible MM patients included in clinical trials. Clinical variable and survival data were collected from 7291 MM patients from Czech Republic, France, Germany, Italy, Korea, Spain, the Nordic Myeloma Study Group and the United States. Kaplan-Meier curves were used to assess progression-free survival (PFS) and overall survival (OS). Relative survival (RS) and statistical cure fractions (CF) were computed for all patients with available data. RESULTS: achieving CR at 1 year was associated with superior PFS (median PFS 3.3 years vs. 2.6 years, p < 0.0001) as well as OS (median OS 8.5 years vs. 6.3 years, p < 0.0001). Clinical variables at diagnosis associated with 5-year survival and 10-year survival were compared with those associated with 2-year death. In multivariate analysis, age over 65 years (OR 1.87, p = 0.002), IgA Isotype (OR 1.53, p = 0.004), low albumin < 3.5 g/dL (OR = 1.36, p = 0.023), elevated beta 2 microglobulin ≥ 3.5 mg/dL (OR 1.86, p < 0.001), serum creatinine levels ≥ 2 mg/dL (OR 1.77, p = 0.005), hemoglobin levels < 10 g/dL (OR 1.55, p = 0.003), and platelet count < 150k/μL (OR 2.26, p < 0.001) appeared to be negatively associated with 10-year survival. The relative survival for the cohort was ~0.9, and the statistical cure fraction was 14.3%. CONCLUSIONS: these data identify CR as an important predictor of long-term survival for HDM-ASCT eligible MM patients. They also identify clinical variables reflective of higher disease burden as poor prognostic markers for long-term survival.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028045
003      
CZ-PrNML
005      
20190820095253.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41408-018-0155-7 $2 doi
035    __
$a (PubMed)30470751
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Usmani, Saad Z $u Hematogic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, United States. saad.usmani@atriumhealth.org.
245    10
$a Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project / $c SZ. Usmani, A. Hoering, M. Cavo, JS. Miguel, H. Goldschimdt, R. Hajek, I. Turesson, JJ. Lahuerta, M. Attal, B. Barlogie, JH. Lee, S. Kumar, S. Lenhoff, G. Morgan, SV. Rajkumar, BGM. Durie, P. Moreau,
520    9_
$a PURPOSE: multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-term remissions and survival. The present study examines the clinical features of long-term survival as it correlates to depth of disease response. PATIENTS & METHODS: this was a multi-institutional, international, retrospective analysis of high-dose melphalan-autologous stem cell transplant (HDM-ASCT) eligible MM patients included in clinical trials. Clinical variable and survival data were collected from 7291 MM patients from Czech Republic, France, Germany, Italy, Korea, Spain, the Nordic Myeloma Study Group and the United States. Kaplan-Meier curves were used to assess progression-free survival (PFS) and overall survival (OS). Relative survival (RS) and statistical cure fractions (CF) were computed for all patients with available data. RESULTS: achieving CR at 1 year was associated with superior PFS (median PFS 3.3 years vs. 2.6 years, p < 0.0001) as well as OS (median OS 8.5 years vs. 6.3 years, p < 0.0001). Clinical variables at diagnosis associated with 5-year survival and 10-year survival were compared with those associated with 2-year death. In multivariate analysis, age over 65 years (OR 1.87, p = 0.002), IgA Isotype (OR 1.53, p = 0.004), low albumin < 3.5 g/dL (OR = 1.36, p = 0.023), elevated beta 2 microglobulin ≥ 3.5 mg/dL (OR 1.86, p < 0.001), serum creatinine levels ≥ 2 mg/dL (OR 1.77, p = 0.005), hemoglobin levels < 10 g/dL (OR 1.55, p = 0.003), and platelet count < 150k/μL (OR 2.26, p < 0.001) appeared to be negatively associated with 10-year survival. The relative survival for the cohort was ~0.9, and the statistical cure fraction was 14.3%. CONCLUSIONS: these data identify CR as an important predictor of long-term survival for HDM-ASCT eligible MM patients. They also identify clinical variables reflective of higher disease burden as poor prognostic markers for long-term survival.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologické markery $7 D015415
650    12
$a přežívající onkologičtí pacienti $x statistika a číselné údaje $7 D000073116
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mnohočetný myelom $x diagnóza $x epidemiologie $x mortalita $x terapie $7 D009101
650    _2
$a staging nádorů $7 D009367
650    _2
$a odds ratio $7 D016017
650    _2
$a surveillance populace $7 D011159
650    _2
$a prognóza $7 D011379
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hoering, Antje $u Cancer Research and Biostatistics, Seattle, Washington, United States.
700    1_
$a Cavo, Michele $u Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
700    1_
$a Miguel, Jesus San $u Centro de Investigación Médica Aplicada, IDISNA, CIBERONC, Clinica Universidad de Navarra, Pamplona, Spain.
700    1_
$a Goldschimdt, Hartmut $u Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
700    1_
$a Hajek, Roman $u University Hospital Ostrava and the Faculty of Medicine, CRAB, University of Ostrava Adam Rosenthal, Seattle, United States.
700    1_
$a Turesson, Ingemar $u Department of Hematology, Malmo University Hospital, Malmo, Sweden.
700    1_
$a Lahuerta, Juan Jose $u Hospital Universitario 12 de Octubre, Madrid, Spain.
700    1_
$a Attal, Michel $u Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
700    1_
$a Barlogie, Bart $u Hematology, Mount Sinai University, New York, United States.
700    1_
$a Lee, Jae Hoon $u Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Republic of Korea.
700    1_
$a Kumar, Shaji $u Department of Internal Medicine, Division of Hematology, Mayo clinic, Rochester, MN, United States.
700    1_
$a Lenhoff, Stig $u Skane University Hospital, Lund, Sweden.
700    1_
$a Morgan, Gareth $u MIRT, UAMS, Myeloma Insitute, Little Rock, United States.
700    1_
$a Rajkumar, S Vincent $u Division of Hematology, Mayo Clinic, Rochester, MN, United States.
700    1_
$a Durie, Brian G M $u Hematology/Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, United States.
700    1_
$a Moreau, Philippe $u service d'Hematologie, CHU de Nantes, Nantes, France.
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 8, č. 12 (2018), s. 123
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30470751 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190820095529 $b ABA008
999    __
$a ok $b bmc $g 1433194 $s 1066505
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 8 $c 12 $d 123 $e 20181123 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
GRA    __
$a P50 CA186781 $p NCI NIH HHS $2 United States
GRA    __
$a U10 CA180819 $p NCI NIH HHS $2 United States
GRA    __
$a U10 CA180888 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Archiving options